Irish Venture Capital: Sowing the Seeds - - BioPharm International


Irish Venture Capital: Sowing the Seeds

BioPharm International


Eclipse Clinical Technologies is a clinical informatics company headquartered in Dublin with offices in the US and continental Europe. Eclipse provides multilingual clinical data collection, management, and statistical analysis services to the pharmaceutical, biotechnology, and medical device sectors.

Investment: €2.5m ($2.9 million)

Source: Seroba BioVentures, Enterprise Ireland and a syndicate of Irish investors.

Web site:


Fluorocap is commercializing a new and more-efficient biochip for use by the biotech and life sciences industries. A basic prototype has been developed that provides a 20-fold improvement on current biochip technology. A review of potential customers for the completed product has indicated strong interest in commercial exploitation of the next prototype.

Web site: http://


This company has a strong portfolio of innovative gas sensor technologies to solve unmet needs across a wide range of valuable applications, including packaging permeability testing, food quality, oxygen sensitive package integrity, as well as medical and environmental analysis.

Web site:


Genable has developed an innovative technology for the suppression and replacement of genes. It is potentially applicable to a broad range of dominant-negative genetic diseases, all of which are incurable today. Its lead program has recently completed a proof-of-principle study in retinitis pigmentosa, an eye disease that causes blindness.

Investment: Raised €1.1 million ($1.3 million) in an investment round led by Delta Partners.

Web site:


Merrion is a specialty pharmaceutical company based on proprietary technologies for oral drug delivery acquired from the Elan Corporation in 2003. Merrion has multiple market-ready, advanced oral drug delivery technologies with several significant products already proven in human clinical trials.

Web site:


NEUtekBio commercializes novel diagnostic and prognostic assays aimed at increasing the efficacy of critical drug treatments involving interferons and other cytokines. The company leverages its research programs through its collaboration agreement with the Centre National de la Recherche Scientifique in Paris.

Investment: More than €4 million ($4.7 million) over the last two years.

Source: Growcorp led a €1.8 million ($2.1 million) round; Enterprise Equity has also invested.

Web site:


This drug-development company focuses on regulation of the human immune system. The company has identified a novel approach for eliciting antigen-specific immune-suppression. Two lead products are in advanced pre-clinical studies. Opsona also has an active interest in toll-like receptors.

Investment: €6.25 million ($7.3 million)

Source: Seroba BioVentures and a syndicate of international investors including Inventages of Switzerland and the Genen Fund (the corporate venture arm of Genentech).

Web site:

blog comments powered by Disqus



Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines
Source: BioPharm International,
Click here